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Antenatal CareNew strategies will be critical to reduce infant mortality and severe morbidity — there are still 5.2 million
newborn deaths and stillbirths each year. The decline in newborn mortality has not kept pace with the
reduction in under-five deaths and is slowest in low- and lower-middle-income countries (LMICs).
Maternal immunization is a promising intervention to protect infants when they are most vulnerable
– in utero and their first few months of life, before they can receive their own vaccines. Successfully intro-
ducing new vaccines for pregnant women in LMICs will require collaboration between two fields — (1)
immunization and (2) maternal, newborn and child health — that use different service delivery
approaches, operate under different policy and funding paradigms, and are not always integrated. In
May 2018, stakeholders from these distinct communities convened to identify challenges and opportu-
nities associated with delivering new maternal immunizations. Participants agreed that antenatal care
is a logical platform. However, in many resource-constrained settings, antenatal care providers are
already overburdened, and most women do not receive the recommended number of antenatal visits.
Implementing maternal immunization could help increase antenatal care attendance by offering an addi-
tional safe and effective intervention that women value. Substantial effort is needed to demonstrate the
benefits of maternal immunization to decision-makers and providers, and to ensure that countries and
health systems are ready for introduction. To that end, participants identified the following priorities:
assure coherence of policies for introducing new vaccines for pregnant women and strengthen maternal
health interventions; generate demand for existing, recommended, and new maternal vaccines; conduct
socio-behavioral, health systems and implementation research to shape optimal vaccine delivery strate-
gies; and strengthen antenatal and perinatal care quality. To achieve these aims, collaboration across
fields will be essential. Given that new maternal vaccines are advancing in clinical development, time
is of the essence.
 2020 The Authors. Published by Elsevier Ltd. This is an open access article under theCCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Over the last three decades, concerted efforts have led to a ~60%
reduction in deaths among children under the age of five; however,
the decline in newborn and young infant mortality has not kept
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children under the age of five [1]. Maternal immunization – vacci-
nating women during pregnancy – has emerged as an intervention
with the potential to contribute to the reduction of neonatal
morbidity and mortality, premature births and stillbirths. Clinical
evidence has supported the implementation of maternal immu-
nization programs for influenza, tetanus and pertussis in countries
around the world [2]. By transferring immunity to the fetus in-
utero and through breastfeeding, maternal immunization can pro-
tect newborns from specific infectious diseases in their first weeks
of life — when they are most vulnerable [3,4]. Two promising new
maternal vaccines against respiratory syncytial virus (RSV) and
group B streptococcus (GBS) are in clinical development, with a
first-in-class RSV vaccine marking the first time a vaccine is in
phase 3 clinical development in pregnant women, and pursuing
an indication for use in pregnancy [5,6] https://clinicaltrials.gov/
ct2/show/NCT03765073?term=Pfizer+group+b&draw=2&rank=1.
In May 2018, the Bill & Melinda Gates Foundation convened a
meeting of global immunization and maternal, newborn and child
health (MNCH) stakeholders in Amsterdam to analyze the state of
the field and identify challenges and opportunities associated with
the delivery of maternal vaccines. The meeting, Allies in Maternal
and Newborn Care: Strengthening Services Through Maternal Immu-
nization, established broad consensus on the potential value of
existing and new maternal immunizations, and on antenatal care
services as a logical platform for delivering these vaccines. The
need for active collaboration between MNCH and immunization
stakeholders was a recurrent topic because of the potential chal-
lenges associated with introducing and delivering these vaccines
as part of maternal health services. Here we outline perspectives
that emerged from the meeting, and recommendations for next
steps.2. Maternal immunization: a high impact opportunity for
protecting both mother and child
Every year, approximately 2.5 million neonates die in the first
month of life and an additional 2.6 million are stillborn [1,7].
Approximately 99% of newborn deaths occur in low- and lower-
middle-income countries (LMICs), where infections are a leading
cause of both infant deaths and stillbirths [1,8,9].
A review of evidence suggests that maternal vaccines in devel-
opment against RSV and GBS could help address infectious disease-
related neonatal and infant morbidity and mortality (Fig. 1) [2,10].
An effective vaccine against GBS could also help address pre-term
births, stillbirths and, to some extent, maternal morbidity and
mortality.
Among the vaccines recommended for pregnant women, teta-
nus vaccines are the most widely utilized. Between 1999 and
2018, an estimated 154 million women of childbearing age
received the recommended two doses of tetanus vaccine as part
of the World Health Organization (WHO) Maternal and Neonatal
Tetanus Elimination Program. This has contributed to a 96%
decrease in neonatal tetanus over three decades [11]. Given this
success, efforts are underway to understand the most optimal
delivery strategies for tetanus vaccines to pregnant women during
antenatal care to strengthen this intervention platform and inform
the implementation of other vaccines [12].
In 2012, WHO recommended that countries considering the ini-
tiation or expansion of seasonal influenza vaccination programs
give the highest priority to pregnant women. Vaccination in preg-
nancy can help lower influenza-related mortality and morbidity
among both pregnant women and newborns [13]. Similarly, in
2015 WHO recommended that countries with a high neonatal per-
tussis mortality burden consider vaccinating pregnant womenwith Tdap (tetanus, diphtheria and pertussis) vaccine to protect
against neonatal pertussis [14].
Despite specific recommendations, uptake of maternal immu-
nizations has been mixed across high-, middle-, and low-income
countries [15]. While there are several existing vaccines recom-
mended during pregnancy, wider acceptance of maternal immu-
nization has been limited by the perception that insufficient
safety and efficacy data are available [3]. Uncertainty about the risk
of vaccinating women during pregnancy, coupled with perceived
safety concerns associated with vaccines in general, plus a low tol-
erance for risk in any pregnancy intervention, has hindered the
implementation of maternal immunization [16]. However, follow-
ing the 2009–2010 H1N1 influenza pandemic and a resurgence of
neonatal pertussis mortality in countries that use acellular pertus-
sis infant immunization, there has been increased interest in
maternal immunization, as well as increased support for this strat-
egy based on research [3]. Meeting participants noted that with
maternal vaccines in advanced stages of clinical development,
there is a need to advance dialogue now and begin preparing for
delivery of maternal immunization, given the potential complexity
of delivering these vaccines.3. What is needed to make the case for new maternal
immunizations
RSV is a leading cause of acute lower respiratory infection and is
responsible for an estimated 1.4 million hospital admissions and
27,300 infant deaths worldwide annually [17]. GBS is a major cause
of both sepsis and meningitis in young infants, and a 2015 study
found that it was a leading contributor to 90,000 infant deaths
and 57,000 stillbirths globally, and potentially associated with up
to 3.5 million pre-term births [18]. In addition, GBS is associated
with approximately 17,000 cases of severe morbidity in infants,
including neurodevelopmental impairment after GBS meningitis
and neonatal encephalopathy worldwide. New maternal immu-
nizations in development can potentially help lower mortality as
well as morbidity of these two diseases [16,17,19].
If proven effective, newmaternal vaccines for RSV and GBS have
the potential to reduce infant morbidity and mortality, yet addi-
tional work, such as the generation of evidence on disease burden
and cost-effectiveness, remains to be done to develop a compelling
and comprehensive value proposition for their adoption and to
help policymakers evaluate the role of these vaccines alongside
other interventions. The need for a strong value proposition for
RSV in particular, is pronounced given that the disease is not well
understood within the maternal health and larger global health
community. Better evidence from LMICs on the disease and eco-
nomic burden of RSV and GBS will facilitate decisions to introduce
these vaccines at the global as well as country-level.4. Maternal immunization for GBS: Value beyond newborns and
infants
While the currently-available approach to addressing maternal
GBS – screening during pregnancy and administration of intra-
venous antibiotics during labor – has led to a significant reduction
of GBS early-onset disease in high-income countries, this strategy
is often not feasible in low-income settings and does not address
late-onset GBS disease. Moreover, selective prenatal maternal
GBS culture is not an accurate predictor of early onset GBS disease
in neonates, and widespread antibiotic use may contribute to
antimicrobial resistance and could potentially affect neonatal
microbiome development [20,21]. Given these limitations, new
strategies are needed; and maternal immunization holds promise
for the prevention of GBS infection among neonates and pregnant
Fig. 1. Global distribution of deaths among children under age 5, neonatal by cause, 2016.
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clinical development [22].
Preliminary cost-effectiveness assessments for GBS indicate
that maternal immunization would be a cost-effective intervention
in LMICs in Africa, with cost per disability adjusted life year (DALY)
ratios similar to other recently introduced childhood vaccines [23].
Since disease incidence and case fatality rates are key drivers of
cost-effectiveness figures, reliable, country-specific data on GBS
burden are needed to better inform national decision making. Dur-
ing the meeting, presenters emphasized that country-level data on
disease burden and cost-effectiveness would help individual coun-
tries plan for integration of maternal immunization within the
package of MNCH interventions.
While the primary objective of a GBS vaccine would be to
reduce GBS-associated neonatal sepsis and stillbirths, maternal
immunization for GBS may provide health benefits for women by
reducing maternal infection and adverse pregnancy outcomes
[24]. An effective GBS vaccine may help avert some of the esti-
mated 33,000 cases of maternal invasive GBS disease worldwide
that contribute to maternal morbidity and mortality [18]. It also
could help address some of the potential concerns raised about
existing prevention options, such as the feasibility or cost-
effectiveness of scaling intrapartum antibiotic prophylaxis in
low-resource settings, its potential association with antimicrobial
resistance, and its inability to guard against late onset GBS disease
[21]. The value proposition for GBS vaccines should thus include a
nuanced understanding of the vaccine’s ability to not only reducenewborn and infant mortality, but also to reduce stillbirths and
preterm births, improve delivery outcomes, reduce maternal mor-
bidity and mortality, and improve long-term health outcomes in
both mothers and infants.
5. Maternal immunization for RSV: vaccines on the horizon
The current RSV vaccine pipeline includes 18 vaccine candi-
dates in clinical trials; only two trials have evaluated RSV vaccines
specifically for use in pregnant women [25]. The most advanced
candidate is a RSV Fusion-protein (RSV F) nanoparticle vaccine that
has been tested in a phase 3 trial for an indication specifically in
pregnant women [26,27]. At least two other candidate vaccines
are ready to be evaluated in phase 2 trials in pregnant women.
Preliminary research suggests that a potential RSV vaccine for
use in pregnant women could prevent 4.6–6 million RSV cases
and 66,000–94,000 deaths in infants per year at a cost of $350–
400 per DALY averted. The cost per DALY averted is likely to be
lower in countries eligible for Gavi support [28]. Additionally, an
RSV vaccine could potentially reduce antibiotic use both for RSV
and related, secondary bacterial infections, which in turn could
reduce antimicrobial resistance [29]. Because RSV exerts a broader
toll on pediatric health and health systems than mortality alone,
additional research is needed to illustrate the potential full impact
of maternal immunization in this area. Such research would enable
the value proposition for RSV vaccines to include, for example,
impact on all-cause, pneumonia, and RSV-specific respiratory
Table 1
Potential value proposition of new maternal immunizations for GBS and RSV by population.
POPULATION POTENTIAL VALUE




< 1 year old)
GBS Vaccine  Reduce neonatal morbidity and mortality [18]  Reduce late onset GBS disease
RSV Vaccine  Reduce neonatal morbidity and mortality [17]  Reduce pneumonia and all cause hospitalization and
mortality
 Reduce antibiotic use
Pregnant women GBS Vaccine  Reduce maternal GBS infection
 Reduce maternal morbidity and mortality related
to GBS infection [18]
 Reduce maternal GBS colonization
 Increase antenatal care attendance and uptake of
services
 Improve delivery outcomes
Fetuses GBS Vaccine  Reduce stillbirths and pre-term births related to GBS
infection [18]
 Improve antenatal care delivery and outcomes
Older Children
(<5 years old)
GBS Vaccine  Reduce neurodevelopmental impairment related to GBS
infection [30]
 Reduce long-term sequelae
 Increase child and immunization uptake
 Improve childhood growth and development
RSV Vaccine  Reduce RSV-associated morbidity and mortality in chil-
dren under-five
 Reduce RSV-associated recurrent wheeze and childhood
asthma [31]
 Reduce long-term sequelae
 Increase child and immunization uptake
 Improve childhood growth and development
Health systems RSV and GBS
Vaccine
 Reduce hospitalization among children under-five [16]
 Reduce infant hospitalization rates and health care
expenditures, which could lead to economic benefits for
women
and their families [16]
 Improve quality of antenatal care
 Improve maternal interventions surveillance systems
 Improve vaccine safety surveillance systems
 Improve infant and maternal disease outcomes surveil-
lance systems
 Improve understanding of burden of disease
 Reduce antimicrobial resistance
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early childhood growth and development.
6. Communicating an expanded value proposition for maternal
immunization in LMIC
Given that vaccine candidates for both GBS and RSV for preg-
nant women have the potential to reach licensure within the next
few years, it is increasingly important to plan for their introduction
and successful delivery. To do this, we need to better communicate
the value proposition of maternal immunization. This means clar-
ifying the impact on fetal and neonatal mortality, and also the
potential to reduce stillbirths, avert pre-term births, prevent long
term disability and sequelae, reduce antimicrobial resistance, as
well as reduce maternal morbidity and mortality. Other benefits
may include strengthening existing antenatal care systems,
improving the maternal tetanus immunization platform, improv-
ing perinatal care and the delivery outcomes, and strengthening
and utilizing safety and disease surveillance systems to achieve
implementation and specific outcome goals. Presenters and partic-
ipants identified several elements that should be included in an
expanded case for adopting newmaternal immunizations (Table 1)
[18]:
7. Antenatal care: a challenging but essential platform for
introducing maternal immunization in LMICs
Antenatal care is increasingly viewed as a health care platform
that provides a range of services beyond basic pregnancy care,
which may include malaria services, prevention of mother-to-
child transmission of HIV, and education on preventive health,
including pediatric vaccines, among other interventions. Antenatal
care offers a confluence of factors needed to deliver maternal
immunization: multiple opportunities to access the right target
population to implement interventions at the right time, and qual-
ified health professionals who can potentially deliver the interven-
tion. As such, participants agreed that antenatal care is the most
logical setting to offer maternal immunizations — and to be suc-cessful, the maternal health community must play a prominent
role in planning for introduction of maternal vaccines. It will be
important to address questions and concerns that may arise among
global health stakeholders, practitioners and communities about
the potential impact of maternal immunization on women and
on the provision of antenatal care services.
Delivery of antenatal care services in LMICs often faces its own
challenges, including limited human and financial resources,
inconsistent quality of care, and context-specific barriers women
face in accessing care [32]. Only 64% of women globally are esti-
mated to meet the previously recommended minimum of four
antenatal care visits, and the WHO’s 2016 guidelines now recom-
mend doubling the number of interactions to eight ‘‘contacts.” For-
tunately, the new guidelines increase opportunities for antenatal
visits in the second and third trimester, when maternal vaccination
can be administered, but maternal health stakeholders have
expressed concerns about the potential for maternal immunization
to place an additional burden on overstretched antenatal care sys-
tems. Quality, utilization, infrastructure and capacity issues will
need to be addressed in parallel with the integration of maternal
immunization.
Participants described new approaches to antenatal care that
could help increase coverage and improve quality in a way that
would facilitate successful introduction of new interventions and
address some of the concerns that have been raised. For example,
group antenatal care, an approach to antenatal care that places
women at the same stage of pregnancy in small group cohorts, is
a strategy that is having success in addressing long waits, short vis-
its and poor service quality. The approach, which has been studied
in Kenya, Nigeria and Rwanda, aims to empower women through
participatory, facilitated learning, peer support and clinical assess-
ment. To date, it has resulted in an increased number of visits and
better quality of care — both important to the integration of mater-
nal immunization [33].
New digital technologies also have the potential to improve the
way services are connected across a continuum, from pre-
pregnancy through childhood, resulting in services that are more
coordinated, timely and holistic. For example, new tools and
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visits and maternal immunizations and could follow the mother
and child offering reminders about child immunizations.
Overall, participants agreed that integrated service delivery has
the potential to create a stronger antenatal care platform for the
delivery of various interventions including maternal immuniza-
tions. The availability of newmaternal vaccines could help increase
antenatal care attendance by offering an additional safe and effec-
tive intervention that women value. Some evidence suggests that
integration of other services for malaria, sexually transmitted
infections, HIV/AIDS and tuberculosis have led to improvements
in uptake of ANC services, particularly in settings where the preva-
lence of such conditions is high [34]. Efforts to prepare for their
introduction could also help bring resources to address existing
quality of care and uptake challenges. In addition, decades of expe-
rience fromWHO’s successful Expanded Programme on Immuniza-
tion could be used to support planning and operationalizing
maternal immunization delivery [24].Table 2
Potential research areas to support delivery of new maternal immunizations.
Potential research areas to support delivery of new maternal immunizations
Policy and
planning
 Capture lessons on introducing tetanus toxoid,
influenza, and pertussis vaccines for pregnant
women
 Capture lessons from the integration of other ser-
vices into antenatal care, such as iron/folate supple-
mentation, HIV testing, or malaria screening and
treatment
 Determine optimal models for coordination
between EPI and MNCH teams within Ministries of
Health
Service delivery  Develop optimal vaccine schedules for all maternal
vaccines
 Determine optimal delivery models to maximize
workflows (e.g., between EPI and maternal health
staff)
 Understand best practices for reporting and safety
monitoring for maternal immunizations
Demand
generation
 Develop effective messaging to explain RSV and GBS
disease to pregnant women
 Understand strategies to build pregnant women’s
understanding of the importance of maternal
immunization and its safety
 Understand strategies to build pregnant women’s
trust with providers
 Understand drivers of uptake decisions about vacci-
nes and antenatal care
Capacity and
infrastructure
 Understand best approaches to health care provider
capacity-building for maternal immunization
 Understand best practices in coordination of fund-
ing, human resources, supply, training and supervi-
sion of immunizations, between maternal health
programs and immunization programs
Impact  Determine the impact of integrating maternal
immunization on the quality and utilization of ante-
natal care8. Different worlds: bridging maternal health and
immunization paradigms
Collaboration between programs focused on MNCH and immu-
nization at the global, regional and country levels will be essential
for introducing newmaternal immunizations. At the recent Allies in
Maternal and Newborn Care meeting, a detailed landscape analysis
on the provision of tetanus vaccine to pregnant women identified
attributes associated with successful vaccine delivery strategies
[12]. Some efforts have been made to strengthen relationships
between the immunization and maternal health communities in
anticipation of new maternal vaccines, including a series of meet-
ings that brought together key stakeholders to discuss concerns
and plot a course forward [24,35,36]. Participants also noted that
global adoption of newmaternal immunizations and their effective
delivery within antenatal care will require harmonization of the
different policy processes and ethical paradigms that govern
immunizations and maternal health interventions [24].
Presenters reviewed the highly structured nature of vaccine
policy decision-making processes at the global and regional levels
and shared WHO’s early stage initiative to build a similarly struc-
tured process for MNCH interventions [37]. Participants discussed
the challenges they will face at the country level, where national
adoption will require collaboration between often-siloed programs
and policy decision-makers. Advisory bodies, such as National
Immunization Technical Advisory Groups (NITAGs), can have a
major role in advocating for integrated services. They noted that
integration of these programs is currently most successful at the
service delivery level where, by necessity, a single health care
worker often provides both services.
Maternal immunization also bridges differences between the
ethical paradigms that govern immunization and reproductive
health, and it must account for the interests of both the mother
and the infant. The approach to assessing risk for maternal immu-
nization needs to go beyond the traditional approach for vaccines
in order to include consideration for vaccines that may benefit only
the mother or the infant, acknowledging the importance of a
woman’s interest in protecting her child. Further, while most vac-
cines are delivered as part of routine, ‘‘opt out” services, reproduc-
tive health programming and some maternal health services tend
to promote women’s agency, engaging women in active decision-
making using an ‘‘informed choice” model in which they weigh
their options, risks and benefits. Maternal immunization will need
to straddle these two paradigms. Policy recommendations for new
maternal vaccines will need to be based on appropriate benefit-risk
assessments across different populations and geographies, andpregnant women will need to be empowered to make informed
decisions that are in the best interest of their own health and that
of their child. This decision-making will need to be supported with
data on disease burden and potential vaccine impact, as well as
appropriate safety and effectiveness data to determine and com-
municate the benefit-risk profile. A truly informed decision-
making process will require robust inclusion of women at all levels
of policy development and implementation.9. Preparing for introduction: many questions yet to answer
Questions remain about the most appropriate way to promote
acceptance and uptake, deliver vaccination services within antena-
tal care, and ensure policy-level support. We will need additional
data to strengthen the value proposition in such areas as burden
of disease, safety and effectiveness, as well as cost effectiveness.
We can also learn important lessons from previous service integra-
tion efforts in areas such as malaria, HIV and tuberculosis, to guide
planning for introduction and delivery of maternal immunization.
In addition, implementation research can help define, test and iter-
ate solutions for delivering maternal immunization within antena-
tal care. Meeting participants identified a wide range of priority
needs and actions to support delivery of maternal immunization
(Table 2).
In working to address these outstanding gaps and questions, a
wide variety of stakeholders should be engaged to identify
context-specific research priorities, including the MNCH and
immunization communities, in-country implementing agencies,
women and policymakers. A more inclusive process helps ensure
the relevance of research questions in facilitating eventual uptake
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the research.
10. Where do we go from here?
The Allies in Maternal and Newborn Care meeting clearly demon-
strated consensus among participants on the potential value of
new maternal immunizations and a shared recognition that deliv-
ery through antenatal care offers both challenges and opportuni-
ties. However, preparatory efforts are needed around
strengthening existing systems and fostering awareness and col-
laboration among stakeholders to allow for the smooth introduc-
tion of a new intervention within the antenatal care platform.
Key recommendations from the meeting include:
10.1. Assure coherence of policies for introducing new vaccines for
pregnant women and maternal health products
At the global level, efforts are underway to develop policy pro-
cesses for MNCH interventions that resemble those instituted for
vaccines, such as the Strategic Advisory Group of Experts (SAGE)
on Immunization. Continued harmonization of policy decision-
making at the global, regional, and country levels may enable
smoother introduction of interventions that overlap between
MNCH and vaccines. Maternal immunization could provide an
apt test case for building new, more harmonized approaches to
decision-making.
10.2. Increase awareness and generate demand for new maternal
vaccines
Although the concept is not new, awareness of the potential
benefit offered by maternal immunization is low, particularly in
the MNCH community. Efforts should focus on increasing aware-
ness and sharing of relevant data and information as soon as it
becomes available (e.g., on the burden of disease, guidelines, vac-
cine safety and efficacy), including country-specific data to pro-
mote country ownership. The introduction of new maternal
vaccines requires comprehensive communications strategies to
foster dialogue among country and regional stakeholders, provi-
ders, communities and women, and the cultivation of champions
at multiple levels. Once these new maternal vaccines become
available, communications and advocacy frameworks should pro-
mote country-level political support to ensure relevant policies
are in place for national adoption.
10.3. Conduct socio-behavioral, health systems and implementation
research to shape optimal delivery strategies
We have much to learn to prepare for new maternal immuniza-
tions. As part of a pre-implementation learning agenda, the field
needs a prioritized portfolio of research to identify best practices,
address potential challenges and apply lessons from previous
efforts, including the introduction of tetanus toxoid, and influenza,
and pertussis vaccines for pregnant women in LMIC, and the intro-
duction of other services into antenatal care.
10.4. Strengthen antenatal care quality
Improving the quality of antenatal care services is an important
first step in planning for the introduction of new maternal vac-
cines. New strategies to deliver antenatal care, including group
antenatal care, have the potential to strengthen the quality of preg-
nancy care and prepare a platform that can reach pregnant women
with a range of interventions. If proven effective and feasible, weshould scale new antenatal care approaches in LMICs that could
facilitate the delivery of new maternal immunizations as they
become available. Maternal vaccines are one component of high-
quality antenatal care services for those women who are most vul-
nerable. Decades of experience from successful immunization pro-
gramming can also be applied to help improve the uptake and
quality of these antenatal care services.
To achieve these aims and realize the promise of maternal
immunization for women and newborns, collaboration across all
relevant fields and disciplines will be essential. Given that new
maternal vaccines are advancing in clinical development, time is
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